Among these, bladder tumor antigen (BTA Stat and BTA TRAK tests), nuclear matrix protein 22 (NMP-22 enzyme linked immunosorbent assay detection kit) and recently tumor-associated antigens such as M344, 19A211, and LDQ19 (ImmunoCyt fluorescence test), fibrinogen-fibrin degradation products (FDP test), and the UroVysion fluorescent in situ hybridization assay have achieved Food and Drug Administration approval for diagnostic purposes. Here, NUMA1 is linked to neoplasm.